Oyster Point Pharma’s dry eye disease treatment met both sign and symptom primary endpoints in a phase 2b clinical trial, the company announced in a press release.
OC-02, a nicotinic acetylcholine receptor agonist, is delivered as a nasal spray and stimulates the trigeminal parasympathetic pathway to activate the glands that produce the eye’s natural tear film, the release said.
A total of 165 patients with dry eye disease were evaluated in the dose-ranging, randomized, double-masked, vehicle-controlled PEARL study.
Patients who received the 2% dose had a mean change in Schirmer’s
Uncategorized